QIAGEN powered by

Saturday, December 1, 2018

QIAGEN launches QCI Interpret bioinformatics features for blood cancers

Introducing a novel myeloid gene panel for the GeneReader NGS System with integrated variant analysis, interpretation and reporting from QIAGEN Clinical Insight (QCI) Interpret for Myeloid Malignancies and

Today, at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, QIAGEN announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QCI Interpret bioinformatics solution for hematological malignancies, and the new QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research as a Sample to Insight workflow on QIAGEN’s GeneReader NGS System.


Read the full press release here.

Learn more about QCI Interpret for Myeloid Malignancies here.

Attending ASH 2018?

Meet and talk with our experts at ASH 18booth #1557!

Featured Products and Solutions

  • QIAGEN’s ipsogen portfolio: a wide range of CE-IVD marked oncohematology diagnostic assays for determining an individual’s biomarker status.
  • QIAact Myeloid DNA UMI Panel: a complete Sample to Insight assay.
  • QIAseq Targeted DNA Human Myeloid Neoplasms Panel: a complete Sample to Insight digital DNA sequencing solution.
  • QCI Analyze and QCI Interpret for Myeloid Malignancies: secondary and tertiary NGS analysis platform with a specialized prognostic workflow.